CAMK2D

CAMK2D (CaMKIIδ) is a calcium/calmodulin-dependent serine/threonine kinase whose subcellular targeting, splice-isoform identity, and activation state determine context-specific signaling outputs across cardiac, mitotic, and oncogenic settings (PMID:42082791, PMID:41487088, PMID:42152470). In the heart, CAMK2D overactivation—rather than mis-splicing itself—is the central pathogenic driver of RBM20 cardiomyopathy, established by genetic epistasis in which Rbm20/Camk2d double-knockout mice are protected and re-expression of individual splice variants reintroduces dysfunction, with the ATP-competitive CaMKII inhibitor hesperadin rescuing function in vivo (PMID:42082791). Cardiac CAMK2D activity is amplified by the scaffold protein BBLN, which physically binds and activates the kinase to promote inflammation, fibrosis, and necroptosis (PMID:38666071). Alternative splicing produces a nuclear variant (CAMK2D-B); phosphorylation near its nuclear localization signal under adrenergic stress restricts it to the cytosol, where it remodels the cardiomyocyte phosphoproteome and blunts calcium transients distinctly from the nuclear-competent form (PMID:41487088). Beyond the heart, phospho-Thr287 CAMK2D scaffolds the RNF8–MAD2 complex through the RNF8 FHA domain to sustain the spindle assembly checkpoint in glioma stem cells (PMID:37468549), and a specific exon-7-containing isoform (isoform 15) directly binds AKT and promotes its Thr308 phosphorylation to confer drug resistance (PMID:42152470). In humans, gain-of-function CAMK2D variants cause dilated cardiomyopathy with neurodevelopmental disorder, whereas loss-of-function variants produce neurological phenotypes alone (PMID:38272033). CAMK2D kinase activity additionally functions as a phosphorylation hub in injury and cancer contexts, phosphorylating Tau at Ser324 to drive ferroptosis (PMID:38634567) and acting downstream of stress signals in intestinal ischemia-reperfusion injury (PMID:42145667).

1. 2023 High

   Established a non-catalytic scaffolding role for activated CAMK2D outside the cardiac context, linking it to mitotic checkpoint control.

   Evidence RNF8 proximity proteomics, Co-IP, FHA/RING domain mutagenesis, and mitotic progression assays in glioma stem cells

   PMID:37468549

   Open questions at the time

   • Whether this scaffolding function operates in non-glioma cell types is untested
   • The kinase substrate(s) of CAMK2D in this checkpoint context, if any, are not defined
   • Upstream signals driving Thr287 phosphorylation in this setting are unaddressed
2. 2023 High

   Identified BBLN as a direct physical activator of CAMK2D that converts kinase activation into cardiac pathology, defining an upstream control point.

   Evidence BBLN overexpression mouse model, CAMK2D-binding-deficient BBLN mutant, and CAMK2D siRNA epistasis with cardiac readouts

   PMID:38666071

   Open questions at the time

   • The structural basis of BBLN–CAMK2D binding is not resolved
   • Whether BBLN regulates CAMK2D in non-cardiac tissues is unknown
3. 2024 Medium

   Resolved the genotype-phenotype logic of human CAMK2D variants, showing that gain- versus loss-of-function dictates cardiac plus neurodevelopmental versus neurological-only disease.

   Evidence Patient cohort variant functional characterization with gain- and loss-of-function testing in mouse and human genetic systems

   PMID:38272033

   Open questions at the time

   • Mechanistic detail beyond GoF/LoF classification is limited
   • Isoform-specific contributions to each phenotype are not separated
4. 2024 Medium

   Showed CAMK2D can be recruited into a defined RNA-protein complex to phosphorylate a specific substrate residue and trigger ferroptosis, expanding its substrate repertoire beyond canonical targets.

   Evidence Co-IP/complex formation, Ser324 site identification, and ferroptosis rescue in ovarian cancer metastasis models

   PMID:38634567

   Open questions at the time

   • Phosphorylation site evidence is from abstract-level description
   • Not independently confirmed in other systems
   • How circRNA/14-3-3 directs CAMK2D specificity is not structurally defined
5. 2026 High

   Demonstrated by genetic epistasis that CAMK2D overactivation, not RBM20 mis-splicing per se, is the actionable driver of RBM20 cardiomyopathy.

   Evidence Rbm20/Camk2d double-KO rescue, splice-variant re-expression, phosphoproteomics, and hesperadin pharmacology in knockin mice

   PMID:42082791

   Open questions at the time

   • Which CAMK2D phosphosubstrates mediate the protective effect is not fully enumerated
   • Long-term efficacy and specificity of CaMKII inhibition in humans is untested
6. 2026 High

   Defined how NLS-proximal phosphorylation reroutes the nuclear CAMK2D-B isoform to the cytosol, producing distinct phosphoproteomic and calcium-handling outcomes under adrenergic stress.

   Evidence Human myocardium RNA-seq/phosphoproteomics, subcellular fractionation, and engineered heart tissue calcium transient assays

   PMID:41487088

   Open questions at the time

   • The kinase responsible for the NLS-proximal phosphorylation is not identified
   • How cytosolic versus nuclear localization maps onto specific disease outcomes is incomplete
7. 2026 Medium

   Linked a specific exon-7-containing CAMK2D isoform to direct AKT activation and drug resistance, establishing isoform-selective oncogenic signaling.

   Evidence Co-IP, AKT Thr308 phosphorylation assay, isoform manipulation in vitro and xenografts, with SNRPA1 splicing regulation

   PMID:42152470

   Open questions at the time

   • Whether AKT Thr308 phosphorylation is direct or kinase-dependent is not fully dissected
   • Single-lab finding without reciprocal validation
8. 2026 Medium

   Extended CAMK2D hyperactivation as a driver of epithelial apoptosis and barrier disruption to intestinal ischemia-reperfusion injury, with pharmacological reversibility.

   Evidence siRNA knockdown, OGD/R and murine I/R models, phospho-westerns, and rapamycin modulation with docking

   PMID:42145667

   Open questions at the time

   • Direct substrates in the intestinal context are not identified
   • Rapamycin–CAMK2D relationship rests partly on docking
9. 2025 Medium

   Identified a protective, CFI-upregulating role for CAMK2D in retinal pigment epithelium against oxidative degeneration, contrasting its pathogenic roles elsewhere.

   Evidence AAV/lentiviral overexpression and knockdown in mouse RPE and ARPE-19 cells with CFI knockdown epistasis

   PMID:39873650

   Open questions at the time

   • The mechanism linking CAMK2D activity to CFI transcription is undefined
   • Single-lab finding
10. 2023 Medium

    Associated CAMK2D kinase activity with a targetable vulnerability in BAP1-deficient mesothelioma.

    Evidence BAP1-KO cells, expression profiling, and KN-93 inhibition in vitro and in xenografts

    PMID:37479714

    Open questions at the time

    • The molecular link between BAP1 loss and CAMK2D dependence is not defined
    • KN-93 selectivity for CAMK2D over other CaMKII isoforms is a confound

• The full substrate map of CAMK2D across its cardiac, mitotic, and oncogenic contexts, and how splice-isoform identity and localization deterministically select those substrates, remains unresolved.
• No unified substrate-specificity model across tissues
• Structural basis of isoform- and partner-directed targeting is missing
• Upstream kinases controlling NLS-proximal and Thr287/Thr287-equivalent phosphorylation events not fully mapped